Gamma oryzanol is a rice-bran antioxidant whose most dependable effect is a modest drop in total and bad cholesterol by blocking gut absorption, alongside a measurable rise in the body's own antioxidant defenses. Traditional uses for menopausal hot flashes and mild anxiety are plausible but weakly supported. It is inexpensive and well tolerated, with a reassuring safety record. (Full Review)

Protocol

Standard Dose

300 mg/day

Common supplemental range 100–600 mg daily

Timing

With a fatty meal

Evening dose with dinner preferred for the calming effect

Dosing Schedule

Split 2–3× daily

Short half-life; once-daily with the largest meal also used

Time to effect

Cholesterol

~4 weeks

Fuller effects by 8–12 weeks

Antioxidant Capacity

~4 weeks

Dose-dependent rise in a controlled trial

Menopausal Symptoms

4–8 weeks

When they occur

Benefits

High: Total and LDL cholesterol reduction

Medium: Increased blood antioxidant capacity; triglyceride reduction

Low: Menopausal and climacteric symptom relief; anti-inflammatory effects; glycemic control support; skin barrier improvement

Speculative: Anxiety and mood support; ergogenic and anabolic enhancement; liver protection

Contraindications

Rice allergy

Pregnancy or breastfeeding

Surgery within ~2 weeks

Poorly controlled thyroid or hormone-sensitive conditions

Key Interactions

Statins and other lipid-lowering drugs

Plant sterol and fiber supplements

Anticoagulants and antiplatelet agents (warfarin, apixaban, aspirin, clopidogrel)

Antidiabetic medications (metformin, sulfonylureas, insulin)

Antihypertensive drugs (amlodipine, lisinopril, losartan)

Fat-soluble nutrient absorption

Sedatives and central nervous system depressants

Risk & Side Effects

High: Mild gastrointestinal discomfort

Medium: Drowsiness and central nervous system sedation; rice-related hypersensitivity or allergy

Low: Hormonal and endocrine modulation; theoretical bleeding risk

Speculative: Unknown long-term safety at high supplemental doses; thyroid axis modulation

Monitoring

Marker	Target	Why
LDL cholesterol (LDL-C)	< 100 mg/dL (often < 70 for higher-risk goals)	Primary target of the cholesterol effect
Total cholesterol (TC)	< 180 mg/dL	Overall lipid burden
Triglycerides (TG)	< 90 mg/dL	Secondary lipid target and metabolic marker
HDL cholesterol (HDL-C)	> 50 mg/dL (women), > 40 mg/dL (men)	Ensures overall lipid balance not worsened
High-sensitivity C-reactive protein (hs-CRP)	< 1.0 mg/L	Tracks the anti-inflammatory effect
Fasting glucose	70–85 mg/dL	Monitors glycemic support and drug interactions
Hemoglobin A1c (HbA1c)	< 5.4%	Longer-term blood sugar control
ALT / AST (liver enzymes)	ALT < 25 U/L (men), < 20 U/L (women)	Safety monitoring and fatty-liver context

Cadence: Recheck lipids ~8 weeks after starting, then every 3–6 months; metabolic and liver markers every 6–12 months

Qualitative Assessment

Menopausal comfort — frequency and intensity of hot flashes
Energy and mood — general sense of calm or wellbeing
Digestive tolerance — absence of nausea or stomach upset
Sleep quality — whether an evening dose improves or disturbs sleep

Gamma Oryzanol for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment